March 06, 2015 1:29 PM ET

Healthcare Equipment and Supplies

Company Overview of Dune Medical Devices Corporation

Company Overview

Dune Medical Devices Corporation develops a tissue characterization technology that enables surgeons and radiologists to detect cancer in real-time. It offers MarginProbe System, a technology that detects cancer by assessing the electromagnetic response of tissue, as well as delivers real-time assessment on excised tissue in breast cancer surgery. The company was founded in 2002 and is based in Caesarea, Israel. It also has offices in Boston and Framingham, Massachusetts; Israel; and Switzerland.

20 Alon Hatavor Street

Industrial Park South

Caesarea,  38900


Founded in 2002


972 4 617 8000


972 4 627 0642

Key Executives for Dune Medical Devices Corporation

Chief Executive Officer and Director
Age: 63
Founder, President, Chief Technology Officer and Director
Chief Medical Advisor
Vice President of Finance & Administration
Vice President of Research, Development and Engineering
Compensation as of Fiscal Year 2014.

Dune Medical Devices Corporation Key Developments

Dune Medical Devices Announces FDA Approval of Updated Version of MarginProbe

Dune Medical Devices announced FDA approval of an updated version of its product, MarginProbe, a medical device that enables real-time detection of cancer at the surface of excised tissue specimens during breast-conserving cancer surgery. Surgeon feedback, innovative design ideas, and superior miniaturization engineering were the driving forces behind the development of MarginProbe 1.2. This new version, which utilizes the same trusted, FDA-approved, diagnostic technology as version 1.1, is focused on proving superior functionality, portability, and overall ease of use. Feature enhancements for MarginProbe 1.2 include: onReduced Size & Weight: A major highlight of MarginProbe 1.2 is the reduced size. The new unit is in tabletop form (29 x 43 x 38 cm in size) and weighs 35 lbs. making it 75% lighter and much easier to handle in busy operating rooms. onBrighter Screen: The screen's brightness has been enhanced to provide surgeons a clearer screen image. onWider Viewing angle: With MarginProbe 1.2, surgeons will have the ability to clearly view the screen from anywhere in the operating room without encountering a glare, pixilation, or a blind spot. onImproved on-screen notices: Ensuring key alerts are easier to notice in the OR ambiance. onStartup Time Reduced 50%: The startup time for MarginProbe 1.2 is reduced from approximately three minutes to 90 seconds, making MarginProbe's services even more instantaneous. onImproved service time: Due to its new reduced size, technicians are able to provide faster service, reducing down time in case service is needed.

Dune Medical Devices Corporation' MarginProbe System Available in the United States

Dune Medical Devices Corporation announced the MarginProbe System, a breakthrough intra-operative tissue assessment device used during lumpectomy surgery to treat early-stage breast cancer, is now available to patients in the United States, with the installation of the first System at University of California, Irvine Medical Center. Dune Medical Devices will be rolling out the MarginProbe System to additional hospitals across the U.S. in the coming months. The MarginProbe System, which received premarket approval from the US Food and Drug Administration on December 27, 2012, significantly improves surgeons' ability to intra-operatively identify 'cancer on the margin' and significantly reduce pathologically positive margins following a patient's initial lumpectomy surgery.

Dune Medical Devices Corporation Announces Results from the Pivotal Clinical Trial for the Marginprobe System

Dune Medical Devices Corporation announced that results from the pivotal clinical trial for the MarginProbe System, Dune's breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, were presented at the 66th Annual Society of Surgical Oncology (SSO) Cancer Symposium. FDA approval of the MarginProbe System was based on a 664 patient prospective, multi-center, randomized, double arm study to evaluate the effectiveness of MarginProbe System in identifying cancerous tissue along the margins of removed breast tissue during initial lumpectomy procedures. The MarginProbe System, which uses electromagnetic "signatures" to identify healthy and cancerous tissue, was found to be over three times more effective in finding cancer on the margin during lumpectomy, compared to traditional intra-operative imaging and palpation assessment. This enabled surgeons to significantly reduce the number of patients with positive margins following initial surgery.

Similar Private Companies By Industry

Company Name Region
DCS Medical Ltd. Middle East/Africa
Surgical Structure Ltd. Middle East/Africa
SmartLight, Ltd. Middle East/Africa
BiFlow Medical Ltd Middle East/Africa
Pulsecare Ltd. Middle East/Africa

Recent Private Companies Transactions

Private Placement
June 26, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dune Medical Devices Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at